CTIS2023-504975-25-00进行中（未招募）1 期
A phase IV, open, non-randomised, low-intervention clinical trial to evaluate the subjective user experience of Zeqmelit™ 6 mg mouth dissolving film for treatment of acute allergic reaction - ZEQ-001
AcuCort AB0 个研究点目标入组 50 人开始时间: 2023年4月20日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Male or female patients = 18 years of age, willing and able to give written informed consent for participating in the trial who previously have experienced acute allergic reactions and who is currently prescribed betamethasone tablets for treatment of such reactions.
排除标准
- •Patient who cannot handle a web-based eDiary via their own electronic device (phone, tablet)., Patients with other medical conditions that in the opinion of the Investigator would exclude the patient from trial participation., Patients who are pregnant, currently breastfeeding, or intend to become pregnant during the course of the trial.
研究者
相似试验
进行中（未招募）
1 期
Prevention of influenza-associated aspergillosis in critically ill patients with PosaconazoleEUCTR2017-003270-14-BEZ Leuven100
招募中
4 期
A phase IV, interventional, non-blinded, randomized, controlled, multicenter study of posaconazole prophylaxis for the prevention of influenza-associated aspergillosis (IAA) in critically ill patientsInfluenza-associated aspergillosisAspergillus infection on top of influenza1002146010017528NL-OMON46362Radboud Universitair Medisch Centrum55
进行中（未招募）
1 期
Prevention of influenza-associated aspergillosis in critically ill patients with PosaconazoleInvasive aspergillosis in critically ill patients with influenza pneumoniaEUCTR2017-003270-14-NLRadboud University Medical Center88
进行中（未招募）
不适用
A phase IV non-randomized, uncontrolled, open-label, single-center trial to evaluate the safety and efficacy of Macugen (pegaptanib sodium) given by intravitreal injections every 6 weeks in patients with serous pigment epithel detachments (PED) in exudative age-related macular degeneration (AMD)EUCTR2006-006312-30-HUDept. of Ophthalmol, Semmelweis University30
进行中（未招募）
1 期
A phase IV, randomized, open-label, controlled, post-licensure study to evaluate the safety of GlaxoSmithKline Biologicals’ HPV-16/18 L1 VLP AS04 vaccine (Cervarix®) when administered intramuscularly according to a 0, 1, 6-month schedule in females aged 18-25 years. - EPI-HPV-111103o medical condition will be investigated in this study. The study will follow vaccinated females and collect safety data focussing on autoimmune diseases, pregnancy outcomes and SAEs considered to be related to the vaccine.EUCTR2007-006651-39-GBGlaxoSmithKline Biologicals100,000